Chronic hepatitis B viral (HBV) infection remains a significant global health problem.
Evidence‐based guidelines are needed to help providers determine when treatment should …

This article has an accompanying continuing medical education activity on page e16.
Learning Objective: Upon completion of the CME activity, successful learners will be able to …

Our understanding of the natural history of hepatitis B virus (HBV) infection and the potential
for therapy of the resultant disease is continuously improving. New data have become …

Perinatal or mother‐to‐child transmission (MTCT) of hepatitis B virus (HBV) remains the
major risk factor for chronic HBV infection worldwide. In addition to hepatitis B immune …

Background Long-term tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B
(CHB) is associated with sustained viral suppression and regression of fibrosis and cirrhosis …

These guidelines have been written to assist physicians and other health care providers in
the recognition, diagnosis, and management of patients chronically infected with the …

These are the first World Health Organization (WHO) guidelines for the prevention care and
treatment of persons living with CHB infection and complement similar recent published …

Background Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent
inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus …

More effective and less resistance-prone antiviral agents are now available to treat hepatitis
B virus (HBV) infection. Profound, durable, therapeutic HBV DNA suppression to slow and …

Patients with chronic hepatitis B (CHB) can be successfully treated using nucleos (t) ide
analogs (NA), but drug-resistant hepatitis B virus (HBV) mutants frequently arise, leading to …